ETF Trends reported that healthcare exchange-traded funds (ETFs) could receive a boost if “some heavily shorted health care stocks” rally as the year draws to a close, prompting short covering.
ETF Trends reported that healthcare exchange-traded funds (ETFs) could receive a boost if “some heavily shorted health care stocks” rally as the year draws to a close, prompting short covering. Biotechnology ETFs in particular could benefit.
As quoted in the market news:
Although pharmaceuticals stocks and ETFs have … been stellar performers, short interest at the end of last month for Bristol-Myers Squibb (NYSE: BMY) and Pfizer (NYSE: PFE) was $1.9 billion apiece, according to FactSet. For Johnson & Johnson (NYSE: JNJ) and Eli Lilly (NYSE: LLY) short interest at the end of October was $2.7 billion and $1.8 billion, respectively. Short interest in Merck (NYSE: MRK), like J&J and Pfizer a Dow component, was $1.7 billion, according to FactSet.
Those pharmaceuticals stocks combine for 23% of the PowerShares Dynamic Pharmaceuticals Portfolio (NYSEArca: PJP), one of this year’s top-10 sector ETFs. PJP, which is up 26.2% this year, also features solid biotech exposure, meaning it could benefit from potential short covering of those stocks.
The Conversation (0)
Outlook Reports world
Featured Life Science Investing Stocks
Browse Companies
MARKETS
COMMODITIES
CURRENCIES
